Tech Company Financing Transactions
IsomAb Funding Round
IsomAb, based in Nottingham, secured $9.5 million in investment from Broadview Ventures, MEIF Proof of Concept & Early Stage Fund and Science Creates Ventures.
Transaction Overview
Company Name
Announced On
2/20/2024
Transaction Type
Venture Equity
Amount
$9,500,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to carry out further studies in preparation for the start of clinical trials.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Biocity Nottingham Innovation Building Pennyfoot Street
Nottingham, NG1 1GF
UK
Nottingham, NG1 1GF
UK
Phone
Undisclosed
Website
Email Address
Overview
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 2/20/2024: 9am.health venture capital transaction
Next: 2/20/2024: WeedOUT venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs